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Patient and Physician Predictors of FFR/iFR Utilization in ACS and SIHD
Payal Kohli MD1, Andrew Wang2, Peiqi Wang3, Lucy Liu2, Ali Weinstein2, John Spertus4, Jon Piccini5, Jeptha Curtis6, Marty Makary3, Ty J. Gluckman7
Background
• Assessment of coronary physiology represents an important means to guide decision-
making on revascularization of intermediate lesions in patients with both acute coronary 
syndrome (ACS) and stable ischemic heart disease (SIHD)
• Current percutaneous coronary intervention (PCI) guidelines note that fractional flow 
reserve (FFR) is reasonable for the assessment of angiographic intermediate coronary 
lesions (50-70% diameter stenosis) and can be useful for guiding revascularization decisions 
in patients with coronary artery disease (Class IIa, Level A)1
• Measurement of FFR and instantaneous-wave free ratio (iFR) can reduce the cost and 
potential for complications with PCI
• Despite strong support for FFR- and iFR-guided PCI, it remains underutilized in current 
practice2
Results – Acute Coronary Syndrome
• Among 1,042,896 ACS patients, 61,323 (5.9%) received FFR the same day as PCI
• Patients with ACS were less likely to receive FFR/iFR before PCI if they were older, male, 
Black, Asian, or had DM, CKD or PAD
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Hypothesis / Objective
Methods
• We evaluated all patients within a large Medicare claims database undergoing PCI between 
January 1, 2013 to June 30, 2018
• Patients were divided into two cohorts—those with ACS or SIHD
• Patients were excluded if they a) underwent stress testing or another form of functional 
testing within 5 days of PCI (among those with an ACS) or within 60 days of PCI (among 
those with SIHD) or b) had FFR/iFR within 60 days of PCI (to account for staged procedures)
• Only physicians performing >10 PCIs per year were included in the analysis
• A hierarchical logistic regression model was used, where the outcome of the model was 
FFR/iFR on the same day as PCI; independent variables included patient characteristics 
(first-level) and physician characteristics (second-level)
Conclusions
• Use of FFR/iFR prior to PCI was higher in patients with SIHD than ACS
• Almost one-fifth of physicians never used FFR/iFR prior to PCI
• Physicians ≤10 years from medical school graduation had the highest rate of FFR/iFR 
utilization, with a graded decrease in use since
• Patients with ACS or SIHD were less likely to receive FFR/iFR before PCI if they were older, 
male, Black, Asian, or had DM, CKD or PAD
• Utilization of FFR/iFR prior to PCI remains low for ACS and SIHD patients alike
• Greater awareness of FFR/iFR is needed to guide revascularization decisions for those with 
intermediate coronary lesions
Results – Stable Ischemic Heart Disease
• Among 255,213 SIHD patients, 29,373 (11.5%) received FFR the same day as PCI
• Patients with SIHD were less likely to receive FFR/iFR before PCI if they were older, male, 
Black, Asian, or had DM, CKD or PAD
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• There were 1667 (19.3%) physicians who never used FFR/iFR for PCI in ACS and 1071 (18.6%) 
physicians who never used FFR/iFR for PCI in SIHD
• Use of FFR/iFR was inversely correlated with years since medical school graduation for both 
ACS and SIHD patients
• Significantly higher use of FFR/iFR was noted in those ≤10 years out of medical school with a 
graded decrease in use as time since medical school graduation increased
§ 11-20 years: RRACS 0.71 (0.62-0.81, p<0.001), RRSIHD 0.88 (0.70-1.10, p=0.26)
§ 21-30 years: RRACS 0.47 (0.41-0.53, p<0.001), RRSIHD 0.60 (0.48-0.75, p<0.001)
§ ≥31 years : RRACS 0.41 (0.35-0.46, p<0.001), RRSIHD 0.49 (0.39-0.61, p<0.001) 
• No difference was noted between male and female physicians or those practicing in urban 
or rural locations with respect to FFR/iFR utilization in those with ACS or SIHD
• Highest use of FFR/iFR was seen in the Western U.S., with lowest use in the Southern U.S.
• Utilization of FFR/iFR increased in correlation with the number of PCIs performed during the 
study period for those with ACS, but not for those with SIHD
• ACS (referent 11-61 PCIs): 
o 62-132 PCIs: RR 1.18 (1.10-1.26, p<0.001)
o ≥133 PCIs: RR 1.34 (1.25-1.43, p<0.001)
• SIHD (referent 11-21 PCIs):
o 22-40 PCIs: RR 1.03 (0.95-1.11, p=0.53)































































Figure 1. Use rates of FFR/iFR among ACS patients undergoing PCI
Figure 2. Use rates of FFR/iFR among SIHD patients undergoing PCI
Table 1. Characteristics of ACS patients receiving FFR/iFR prior to PCI
Patient characteristic Adjusted odds ratio, 95% CI p-value
Age (years) ≤64 Reference
65-74 0.93 (0.91-0.96) <0.001
75-84 0.78 (0.76-0.80) <0.001
≥85 0.50 (0.48-0.52) <0.001
Sex Male Reference
Female 1.04 (1.02-1.06) <0.001
Race White Reference
Black 0.89 (0.85-0.92) <0.001
Asian 0.88 (0.82-0.95) 0.001
Hispanic 1.00 (0.93-1.07) 0.98
North America Native 1.02 (0.93-1.13) 0.65
Diabetes mellitus Yes 0.98 (0.96-0.99) 0.01
No Reference
Hypertension Yes 1.16 (1.12-1.19) <0.001
No Reference
Chronic kidney disease Yes 0.84 (0.82-0.85) <0.001
No Reference
Hyperlipidemia Yes 1.10 (1.07-1.12) <0.001
No Reference
Ever smoking Yes 0.87 (0.86-0.89) <0.001
No Reference
PAD Yes 0.91 (0.89-0.93) <0.001
No Reference
Patient characteristic Adjusted odds ratio, 95% CI p-value
Age (years) ≤64 Reference
65-74 0.91 (0.87-0.95) <0.001
75-84 0.76 (0.73-0.79) <0.001
≥85 0.58 (0.55-0.62) <0.001
Sex Male Reference
Female 1.07 (1.04-1.10) <0.001
Race White Reference
Black 0.89 (0.84-0.94) <0.001
Asian 0.88 (0.78-1.00) 0.04
Hispanic 0.93 (0.83-1.05) 0.24
North America Native 0.97 (0.82-1.14) 0.67
Diabetes mellitus Yes 0.92 (0.90-0.95) <0.001
No Reference
Hypertension Yes 0.95 (0.91-0.99) 0.02
No Reference
Chronic kidney disease Yes 0.82 (0.79-0.85) <0.001
No Reference
Hyperlipidemia Yes 0.96 (0.93-1.00) 0.03
No Reference
Ever smoking Yes 0.95 (0.92-0.98) 0.001
No Reference
PAD Yes 0.83 (0.80-0.86) <0.001
No Reference
• We sought to characterize patient and physician characteristics associated with utilization 
of FFR/iFR prior to PCI among patients with ACS or SIHD
Results—Physician Characteristics
Table 2. Characteristics of SIHD patients receiving FFR/iFR prior to PCI
